Hangzhou Qihan Biotech Co., Ltd. (CN), a Hangzhou-based biotech specializing in gene editing and cell/organ therapies including cancer treatments, experienced ransomware activity attributed to a global threat actor. The company’s efforts to make immune-privileged cell and xenogeneic organ therapies accessible worldwide were disrupted, impacting data and operations. #China
Incident Details
- Victim: Hangzhou Qihan Biotech Co., Ltd.
- Sector: Healthcare
- Country: CN
- Actor: global
- Source:
- Discovered: 2026-08-28T15:02:27.857650+00:00
- Published: 2026-08-12T00:00:00+00:00
Information
- Hangzhou Qihan Biotech Co., Ltd. is a Hangzhou-based biotech company specializing in gene editing and cell and organ therapies.
- The company develops immune-privileged cells and xenogeneic organs to treat cancer and organ failure.
- It aims to make these therapies accessible worldwide.
Disclaimer: This post is based on public claims made by the ransomware group "global". I cannot confirm the accuracy of the information. However, I would be happy to share any official statement from the affected organization to provide clarification.